KSC Healthcare Drug Manufacturers - Specialty & Generic 001060.KS

JW Pharmaceutical Corporation

$ 26 700.00 -2.02 %

JW Pharmaceutical Corporation, established in 1945 and headquartered in Seoul, South Korea, operates globally, focusing on the development, manufacturing, and distribution of a comprehensive range of pharmaceuticals and medical supplies. Its diverse product portfolio addresses numerous therapeutic areas, including cardiovascular, gastrointestinal, urinary, and metabolic health, as well as infectious diseases, women's health, renal and central nervous system disorders, anti-anemic treatments, respiratory ailments, rheumatic arthritis, oncology, anesthesia, antidotes, and advanced nutritional support.

CEO: Young-Sub Shin - https://www.jw-pharma.co.kr

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 64 808.36

Loading data...

001060.KS vs S&P500

Loading data...

No data available.

Quick ratio

0.92

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

24.24

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1 101.50

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

20.03 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

16.79 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

8.39

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.14

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

2 742.95

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

15.47 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
3.98 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.10 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.09 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.